Partnering

The Apogee of Therapeutic Innovation

Partnering

We have completed a Phase I clinical trial for ABC294640 in solid tumor cancers and are starting a Phase Ib/II trial in diffuse large B-cell lymphoma.  We are interested in building relationships for partnering or out-licensing ABC294640 and/or our SK inhibitor platform for expanded clinical development and commercialization.  We are interested in discussing opportunities for accelerating the clinical development of our technology.  We are flexible and open to many forms of relationships.  For more information, please contact Sil Lutkewitte at sil_lutkewitte@apogee-biotech.com.

Intellectual Property

The first US Patent (US 7,338,961) entitled “Sphingosine Kinase Inhibitors”, which covers the ABC294640 compound and several related chemotypes, issued on 03/04/2008.  Multiple additional USPTO and PCT patent applications are pending.

Future looking statements:

Statements herein relating to future product development or business performance or strategies, including expectations regarding preclinical and clinical development, are forward-looking statements. Apogee cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements include, among other things, the following:  our ability to progress any product candidates into pre-clinical or clinical trials; the scope, initiation, rate and progress of our pre-clinical studies and clinical trials and other research and development activities; our products and technology are in the early stages of development and are subject to many risks including technological, operational, safety, regulatory and intellectual property concerns; while we are pleased with our development progress to date, it provides no indication or guaranee as to future development progress; and we will need significant additional funding to achieve our goals and competition for funding is intense, particularly in these economic times.  These forward-looking statements speak only as of the date of their posting and Apogee assumes no duty to update such statements.

Powered by THE BRAVO GROUP & ARCHODA: CREATE SOMETHING UNIQUE